Vaxcell-Bio Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Vaxcell-Bio Therapeutics has a total shareholder equity of ₩83.5B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩85.0B and ₩1.5B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
Interest coverage ratio | n/a |
Cash | ₩50.05b |
Equity | ₩83.49b |
Total liabilities | ₩1.49b |
Total assets | ₩84.98b |
Financial Position Analysis
Short Term Liabilities: A323990's short term assets (₩51.2B) exceed its short term liabilities (₩924.1M).
Long Term Liabilities: A323990's short term assets (₩51.2B) exceed its long term liabilities (₩562.8M).
Debt to Equity History and Analysis
Debt Level: A323990 is debt free.
Reducing Debt: A323990 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A323990 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A323990 has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 22.9% each year.